These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21986842)

  • 1. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
    Sinha S; Lacy M; Mikhael J; Hayman S; Buadi F; Detweiler-Short K; Dispenzieri A; Gertz M; Dingli D; Rajkumar SV; Kumar SK
    Leukemia; 2012 Apr; 26(4):839-41. PubMed ID: 21986842
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
    Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M
    Eur J Haematol; 2005 Nov; 75(5):391-5. PubMed ID: 16191088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
    Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M
    Haematologica; 2001 Apr; 86(4):409-13. PubMed ID: 11325648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
    Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
    Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
    [No Abstract]   [Full Text] [Related]  

  • 6. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
    Barlogie B; Tricot G; Anaissie E; Shaughnessy J; Rasmussen E; van Rhee F; Fassas A; Zangari M; Hollmig K; Pineda-Roman M; Lee C; Talamo G; Thertulien R; Kiwan E; Krishna S; Fox M; Crowley J
    N Engl J Med; 2006 Mar; 354(10):1021-30. PubMed ID: 16525139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
    Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
    Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
    Mohty M; Attal M; Marit G; Bulabois CE; Garban F; Gratecos N; Rio B; Vernant JP; Sotto JJ; Cahn JY; Blaise D; Jouet JP; Facon T; Yakoub-Agha I
    Bone Marrow Transplant; 2005 Jan; 35(2):165-9. PubMed ID: 15531895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
    Milone JH; Prates V; Bordone J; Napal J; Garcia C
    Bone Marrow Transplant; 2003 Aug; 32(3):343. PubMed ID: 12858210
    [No Abstract]   [Full Text] [Related]  

  • 12. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.
    Suzuki T; Kusumoto S; Yoshida T; Mori F; Ito A; Ri M; Ishida T; Komatsu H; Niimi A; Iida S
    Int J Hematol; 2013 Apr; 97(4):540-3. PubMed ID: 23456263
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
    Awan FT; Osman S; Kochuparambil ST; Gibson L; Remick SC; Abraham J; Craig M; Jillella A; Hamadani M
    Bone Marrow Transplant; 2012 Jan; 47(1):146-8. PubMed ID: 21358681
    [No Abstract]   [Full Text] [Related]  

  • 15. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
    Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
    Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
    Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
    Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in allogeneic transplantation for multiple myeloma.
    Gahrton G
    Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
    Steurer M; Spizzo G; Mitterer M; Gastl G
    Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.